Benralizumab pregnancy exposure study

Study identifier:D3250R00026

ClinicalTrials.gov identifier:NCT03794999

EudraCT identifier:N/A

CTIS identifier:N/A

Recruiting

Official Title

The Benralizumab Pregnancy Exposure Study: A VAMPSS Post Marketing Surveillance Study

Medical condition

asthma

Phase

N/A

Healthy volunteers

No

Study drug

Benralizumab-exposure, Exposure to other asthma medications

Sex

Female

Estimated Enrollment

800

Study type

Observational

Age

N/A

Date

Study Start Date: 20 Mar 2019
Estimated Primary Completion Date: 27 Feb 2026
Estimated Study Completion Date: 27 Feb 2026

Study design

Allocation: N/A
Endpoint Classification: -
Intervention Model: -
Masking: -
Primary Purpose: -

Verification:

Verified 01 Nov 2023 by AstraZeneca

Sponsors

AstraZeneca

Collaborators

University of California, San Diego, Department of Pediatrics

Inclusion and exclusion criteria